Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers
35,256,257 Traditionally, GLP-1(936) was considered a metabolically inactive product of GLP-1, losing its primary function of regulating blood sugar
COMPREHENSIVE BASELINE LAB One-on-one provider consultation YOUR ROADMAP TO HEALTHIER, HAPPIER LIVING Fill out the form below and a patient care coordinator will be in touch as soon as possible to help you schedule your first appointment and answer any questions
Tirzepatide activates both pathways, which explains its enhanced effectiveness for both weight loss and metabolic health improvements
Those shortages of brand-name GLP-1s that Barkley mentions helped propel the growth of compounded GLP-1s at Ro and other telehealth companies -- but with the FDA having now declared GLP-1 shortages over, Ro is already done with selling compounded versions
